FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average b	urden									
hours nor reenense:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,													
1. Name and Address of Reporting Person* Seiser Robert A					2. Issuer Name and Ticker or Trading Symbol ACURA PHARMACEUTICALS, INC [ ACUR ]								(Che	eck all applic	,		vner			
(Last)	(Last) (First) (Middle)														below)			below)	specify	
C/O ACURA PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/03/2023									VP, Treasurer & Controller						
616 N. NORTH COURT, SUITE 120						0.1.03,2023														
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) PALATINE IL 60067													X Form filed by One Reporting Person Form filed by More than One Reporting							
(City)	(S	tate)	(Zip)												Person				ung	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Day/Year) i		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		ties Acq d Of (D) (				es For ally (D) Following (I) (		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	ınt (A) or (D)		Price	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock 01/03/					/2023			M <sup>(1)</sup>		20,000 A		(2)	398,	398,254(3)		D				
		-	Fable II - D								osed of, onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, Tr	4. Transactio Code (Inst 8)				6. Date Exercisable an Expiration Date (Month/Day/Year)		)	7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e S Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
									Date		Expiration		O N	umber f						
Restricted				C	ode	V	(A)	(D)	Exercisab	ie   E	Date	Title	+s	hares					$\vdash$	
Stock Unit (2017 Plan)	\$0.01 <sup>(2)</sup>	01/03/2023			М		20,000		(5)		(5)	Commo		0,000	(4)	40,000	0	D		

## **Explanation of Responses:**

- 1. Represents exchange of restricted stock units.
- 2. Par value of \$.01 must be paid by Reporting Person upon exchange of Restricted Stock Units for stock.
- 3. Does not include Restricted Stock Units.
- 4. Not Applicable.
- 5. 60,000 Restricted Stock Units were granted on December 11, 2018 and were 100% vested on December 11, 2019. Distributions in respect of this vested Restricted Stock Units will be made in three equal installments in each of 2021, 2022, and 2023 or earlier upon a qualifying change of control which also meets certain criteria of Section 409A of the Internal Revenue Code.

/s/ Robert A. Seiser

01/05/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.